Supply Chain Intelligence

Inhibikase Therapeutics, Inc. Supply Chain

IKT supply chain intelligence for Inhibikase Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IKT ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
9Customers
2Debt Items
20Related Chains

Inhibikase Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
DNLI Denali Therapeutics Inc. 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
DNLI Denali Therapeutics Inc. 72% Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI gra…
ORANY ORANY 72% o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with ou…
PRTA Prothena Corporation plc 72% Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cos…
PRTA Prothena Corporation plc 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
SNYNF Sanofi 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable co…

Inhibikase Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
ABLI-THERAPEUTICS-INC ABLI-THERAPEUTICS-INC 90% In exchange for the exclusive license rights, ABLi made a non-refundable, non-creditable payment of one dollar.
DNLI Denali Therapeutics Inc. 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
DNLI Denali Therapeutics Inc. 72% Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cos…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IKT graph: Reciprocal relationship from ORANY …
ORANY ORANY 72% o build a sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.…
PRTA Prothena Corporation plc 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
PRTA Prothena Corporation plc 72% Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: Reciprocal relationship from PRTA graph: Reciprocal relationship from IKT graph: Reciprocal relationship from PRTA gra…
SNYNF Sanofi 72% tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obtains regulatory approval, we may be unabl…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: Reciprocal relationship from SNYNF …

Inhibikase Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IKT-DEBT-10222 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-28.
IKT-DEBT-10221 Warrants outstanding: 1937985 90% xbrl warrant detail from xbrl 2023-03-31.

Inhibikase Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Inhibikase Therapeutics, Inc..

Inhibikase Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
IKT-OWNER-SANDS-CAPITAL-ALTERNATIVES-LLC Sands Capital Alternatives, LLC 90% 13F overlay lists Sands Capital Alternatives, LLC as top holder; 104 tracked holders.

Inhibikase Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DNLI Denali Therapeutics Inc. 100.00 1 ['customer', 'supplier']
LQDA Liquidia Corporation 100.00 2
PRTA Prothena Corporation plc 100.00 1 ['customer', 'supplier']
ORANY ORANGE 100.00 1 ['customer', 'supplier']
SNYNF Sanofi 100.00 1 ['customer', 'supplier']
XOMAP XOMA Royalty Corporation 100.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
AMZE Amaze Holdings, Inc. 50.00 2
BLTE Belite Bio, Inc 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
ANL Adlai Nortye Ltd. 50.00 2
ANRO Alto Neuroscience, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
ALXO ALX Oncology Holdings Inc. 50.00 2
CHUC Charlie's Holdings, Inc. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
CLNE Clean Energy Fuels Corp. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
View IKT supply chain intel →

Explore the full interactive supply chain map for Inhibikase Therapeutics, Inc..

Open IKT supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map